Aberrant DNA methylation in malignant melanoma

Malignant melanoma remains one of the most deadly human cancers with no effective cures for metastatic disease. The poor efficacy of current therapy in advanced melanoma highlights the need for better understanding of molecular mechanisms contributing to the disease. Recent work has shown that epigenetic changes, including aberrant DNA methylation, lead to alterations in gene expression and are as important in the development of malignant melanoma as the specific and well-characterized genetic events. Reversion of these methylation patterns could thus lead to a more targeted therapy and are currently under clinical investigation. The purpose of this review is to compile recent information on aberrant DNA methylation of melanoma, to highlight key genes and molecular pathways in melanoma development, which have been found to be epigenetically altered and to provide insight as to how DNA methylation might serve as targeted treatment option as well as a molecular and prognostic marker in malignant melanoma.

[1]  Yao-Tseng Chen,et al.  Cancer/testis (CT) antigens: Potential targets for immunotherapy , 2009, Cancer science.

[2]  T. Deng,et al.  An essential role for DNA methyltransferase 3a in melanoma tumorigenesis. , 2009, Biochemical and biophysical research communications.

[3]  S. Ariyan,et al.  Genome-wide screen of promoter methylation identifies novel markers in melanoma. , 2009, Genome research.

[4]  D. Morton,et al.  CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma , 2009, Clinical Cancer Research.

[5]  Michael Krauthammer,et al.  Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications , 2009, PloS one.

[6]  O. Fodstad,et al.  Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling , 2008, Pigment cell & melanoma research.

[7]  D. Polsky,et al.  Frequent p16-independent inactivation of p14ARF in human melanoma. , 2008, Journal of the National Cancer Institute.

[8]  Guillermo Garcia-Manero,et al.  Evolution of decitabine development , 2008, Cancer.

[9]  E. Borden,et al.  Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL , 2008, Oncogene.

[10]  P. Dupont,et al.  Clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma patients is associated with a specific gene profile present prior to treatment , 2008 .

[11]  P. Guldberg,et al.  The genome and epigenome of malignant melanoma , 2007, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[12]  H. Donninger,et al.  The RASSF1A tumor suppressor , 2007, Journal of Cell Science.

[13]  X. C. Xu Tumor-suppressive activity of retinoic acid receptor-β in cancer , 2007 .

[14]  Y. Miyagi,et al.  Silencing of tissue factor pathway inhibitor‐2 gene in malignant melanomas , 2007, International journal of cancer.

[15]  A. Bosserhoff,et al.  Loss of maspin expression contributes to a more invasive potential in malignant melanoma. , 2007, Pigment cell research.

[16]  A. Bosserhoff,et al.  Epigenetic events in malignant melanoma. , 2007, Pigment cell research.

[17]  Xìao-chun Xu Tumor-suppressive activity of retinoic acid receptor-beta in cancer. , 2007, Cancer letters.

[18]  M. Bosenberg,et al.  Epigenetic silencing of novel tumor suppressors in malignant melanoma. , 2006, Cancer research.

[19]  E. Borden,et al.  Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Kelly B. Moran,et al.  Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[21]  Jian-Kang Zhu,et al.  Role of the Arabidopsis DNA glycosylase/lyase ROS1 in active DNA demethylation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Alessandra Marini,et al.  Epigenetic silencing of the PTEN gene in melanoma. , 2006, Cancer research.

[23]  T. Ushijima,et al.  Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. , 2006, Cancer research.

[24]  S. Ferrone,et al.  Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells , 2006, Oncogene.

[25]  A. Mirmohammadsadegh,et al.  Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. , 2006, The Journal of investigative dermatology.

[26]  K. Niedojadło,et al.  Apaf-1 expression in human cutaneous melanoma progression and in pigmented nevi. , 2006, Pigment cell research.

[27]  M. Millward,et al.  Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. , 2006, The Journal of investigative dermatology.

[28]  S. O’Day,et al.  Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Ajani,et al.  Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-β2 expression , 2005, Oncogene.

[30]  S. Baylin,et al.  DNA methylation and gene silencing in cancer , 2005, Nature Clinical Practice Oncology.

[31]  B. Ng,et al.  The RASSF1A Isoform of RASSF1 Promotes Microtubule Stability and Suppresses Tumorigenesis , 2005, Molecular and Cellular Biology.

[32]  Lloyd J. Old,et al.  Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.

[33]  Robert Brown,et al.  Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. , 2005, Carcinogenesis.

[34]  David A Jones,et al.  Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[36]  M. Ueda,et al.  Decreased expression of Apaf-1 with progression of melanoma. , 2005, Pigment cell research.

[37]  A. Hardy Mortality , 2005, The Lancet.

[38]  M. You,et al.  Tumor susceptibility of Rassf1a knockout mice. , 2005, Cancer research.

[39]  C. Rödel,et al.  What is the role of radiotherapy in bladder-preserving cancer therapy? , 2005, Nature Clinical Practice Oncology.

[40]  T. Sugimura,et al.  Promoter methylation profiling of 30 genes in human malignant melanoma , 2004, Cancer science.

[41]  Yuhei Yamamoto,et al.  Epigenetic silencing of E- and P-cadherin gene expression in human melanoma cell lines. , 2004, International journal of oncology.

[42]  J. Cheng,et al.  Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.

[43]  Mark Shackleton,et al.  Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. Guldberg,et al.  Genetic and epigenetic alterations of the APC gene in malignant melanoma , 2004, Oncogene.

[45]  T. Boon,et al.  Promoter-Dependent Mechanism Leading to Selective Hypomethylation within the 5′ Region of Gene MAGE-A1 in Tumor Cells , 2004, Molecular and Cellular Biology.

[46]  D. Morton,et al.  Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients , 2004, Oncogene.

[47]  A. Feinberg,et al.  The history of cancer epigenetics , 2004, Nature Reviews Cancer.

[48]  G. Schwartsmann,et al.  A Phase I Trial of Cisplatin Plus Decitabine, a New DNA-Hypomethylating Agent, in Patients with Advanced Solid Tumors and a Follow-Up Early Phase II Evaluation in Patients with Inoperable Non-Small Cell Lung Cancer , 2000, Investigational New Drugs.

[49]  David A Jones,et al.  Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. , 2004, Molecular pharmacology.

[50]  S. Pavey,et al.  Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. , 2004, International journal of cancer.

[51]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[52]  T. Saida,et al.  ASC/TMS1, a caspase‐1 activating adaptor, is downregulated by aberrant metylation in human melanoma , 2003, International journal of cancer.

[53]  A. Bosserhoff,et al.  Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. , 2003, The American journal of pathology.

[54]  A. Chan,et al.  Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers , 2003, International journal of cancer.

[55]  G. Robertson,et al.  Loss of PTEN promotes tumor development in malignant melanoma. , 2003, Cancer research.

[56]  A. Chan,et al.  Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients , 2003, International journal of cancer.

[57]  R. Jaenisch,et al.  Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.

[58]  G. Pfeifer,et al.  Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. , 2003, Cancer research.

[59]  J. Herman,et al.  A systematic profile of DNA methylation in human cancer cell lines. , 2003, Cancer research.

[60]  P. Laird,et al.  Phase I trial of continuous infusion 5-aza-2′-deoxycytidine , 2003, Cancer Chemotherapy and Pharmacology.

[61]  Rachel Jones,et al.  Behavioural genetics: Worms gang up on bacteria , 2002, Nature Reviews Genetics.

[62]  E. Eisenhauer,et al.  DNA methyltransferase inhibitors-state of the art. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  David Polsky,et al.  Focus on melanoma. , 2002, Cancer cell.

[64]  J. Minna,et al.  Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[66]  P. Laird,et al.  DNA Methyltransferase Deficiency Modifies Cancer Susceptibility in Mice Lacking DNA Mismatch Repair , 2002, Molecular and Cellular Biology.

[67]  A. Bird DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[68]  U. Weidle,et al.  Expression profile of genes coding for melanoma differentiation antigens and cancer/testis antigens in metastatic lesions of human cutaneous melanoma , 2001, Melanoma research.

[69]  L. Aaltonen,et al.  Age-related hypermethylation of the 5' region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. , 2001, Cancer research.

[70]  S. Fulda,et al.  Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer , 2001, Oncogene.

[71]  N. Gruis,et al.  Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. , 2001, Cancer research.

[72]  Keith D Robertson,et al.  DNA methylation, methyltransferases, and cancer , 2001, Oncogene.

[73]  T. Kouzarides,et al.  Dnmt3a binds deacetylases and is recruited by a sequence‐specific repressor to silence transcription , 2001, The EMBO journal.

[74]  J. Issa,et al.  Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications , 2001, Annals of Internal Medicine.

[75]  J. Minna,et al.  Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.

[76]  J. Pablos Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001 .

[77]  P. Jones,et al.  Cancer: Death and methylation , 2001, Nature.

[78]  T. Bestor,et al.  The DNA methyltransferases of mammals. , 2000, Human molecular genetics.

[79]  S. Baylin,et al.  DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci , 2000, Nature Genetics.

[80]  Chun Xing Li,et al.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.

[81]  Peter L. Jones,et al.  DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters , 2000, Nature Genetics.

[82]  J. Herman,et al.  CpG methylation is maintained in human cancer cells lacking DNMT1 , 2000, Nature.

[83]  J. Herman,et al.  DNA hypermethylation in tumorigenesis: epigenetics joins genetics. , 2000, Trends in genetics : TIG.

[84]  M. Lübbert,et al.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  M. Tang,et al.  Mutation hotspots and DNA methylation. , 2000, Current topics in microbiology and immunology.

[86]  M. Lübbert,et al.  DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. , 2000, Current topics in microbiology and immunology.

[87]  Luke Hughes-Davies,et al.  DNA methyltransferase Dnmt1 associates with histone deacetylase activity , 2000, Nature Genetics.

[88]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[89]  R. Elashoff,et al.  Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  S. Lowe,et al.  Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. , 1999, Science.

[91]  J. Herman,et al.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[92]  G. Walker,et al.  Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets , 1998, Genes, chromosomes & cancer.

[93]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[94]  N. Hayward,et al.  Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. , 1997, Cancer research.

[95]  L. Chin,et al.  Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. , 1997, Genes & development.

[96]  K. Bélanger,et al.  Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. , 1997, Anti-cancer drugs.

[97]  M. Loda,et al.  Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. , 1997, Cancer research.

[98]  F. McCormick,et al.  Signal transduction from multiple Ras effectors. , 1997, Current opinion in genetics & development.

[99]  R. Kothary,et al.  Lung tumors in mice expressing an antisense RARβ2 transgene , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[100]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[101]  Rika Deraemaecker,et al.  Expression of MAGE genes in primary and metastatic cutaneous melanoma , 1995, International journal of cancer.

[102]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[103]  J S Lee,et al.  Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. , 1995, The New England journal of medicine.

[104]  R. Jaenisch,et al.  Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[105]  B. Houle,et al.  Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[106]  V. Zagonel,et al.  5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. , 1993, Leukemia.

[107]  J C Briggs,et al.  Cutaneous melanoma. , 1993, Journal of the American Academy of Dermatology.

[108]  M. van Glabbeke,et al.  The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. , 1987, European journal of cancer & clinical oncology.

[109]  G. Rivard,et al.  Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. , 1985, Pharmacology & therapeutics.

[110]  M. N. Epstein,et al.  A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. , 1984, Human pathology.

[111]  R. Momparler,et al.  Incorporation of 5-Aza-2'-deoxycytidine-5'-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. , 1983, Molecular pharmacology.

[112]  P. Barr,et al.  On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs , 1983, Cell.

[113]  A. Feinberg,et al.  Hypomethylation distinguishes genes of some human cancers from their normal counterparts , 1983, Nature.

[114]  Kun-Tsan Lin,et al.  Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. , 1981, Leukemia research.

[115]  Philip J. Farabaugh,et al.  Molecular basis of base substitution hotspots in Escherichia coli , 1978, Nature.

[116]  M. Rosenberg,et al.  In situ hybridization of repetitive monkey genome sequences isolated from defective simian virus 40 DNA , 1976, Cell.

[117]  U. G. Dailey Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.